{
    "clinical_study": {
        "@rank": "112583", 
        "arm_group": {
            "arm_group_label": "Drug-packaging Microparticles", 
            "arm_group_type": "Experimental", 
            "description": "Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week."
        }, 
        "brief_summary": {
            "textblock": "Malignant ascites and pleural effusion are common symptoms in patients with advanced cancer.\n      Currently, the management of malignant ascites and pleural effusion  is a considerable\n      clinical challenge. The investigator hypothesized that tumor cell-derived microparticles\n      packaging chemotherapeutic drugs might be a useful means to treat malignant ascites and\n      pleural effusion. Thirty malignant ascites or pleural effusion patients will be recruited\n      for Phase II clinical trials."
        }, 
        "brief_title": "Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Malignant Pleural Effusion,", 
            "Malignant Ascites"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ascites", 
                "Pleural Effusion", 
                "Pleural Effusion, Malignant"
            ]
        }, 
        "detailed_description": {
            "textblock": "Ascites or pleural effusion were first removed from patients. The patients were then locally\n      injected with microparticles packaging chemotherapeutic drugs 4 times a week. The\n      therapeutic effects and side effects were recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of malignant ascites or malignant pleural effusion\n\n        Exclusion Criteria:\n\n          -  Non-malignant ascites or pleural effusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854866", 
            "org_study_id": "Soundny Biotech"
        }, 
        "intervention": {
            "arm_group_label": "Drug-packaging Microparticles", 
            "description": "Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.", 
            "intervention_name": "Drug-packaging microparticles", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pleural Effusion", 
            "ascites", 
            "Malignant"
        ], 
        "lastchanged_date": "September 28, 2013", 
        "link": {
            "description": "Related information", 
            "url": "http://www.ncbi.nlm.nih.gov/pubmed/23250412"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Wuhan", 
                    "country": "China", 
                    "state": "Hubei", 
                    "zip": "430070"
                }, 
                "name": "Hubei Provincial Traditional Chinese Medical Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Tumor Cell-derived Microparticles Used as Vectors of Chemotherapeutic Drugs to Treat Malignant Ascites and Pleural Effusion", 
        "overall_official": {
            "affiliation": "Huazhong University of Science and Technology", 
            "last_name": "Bo Huang, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Volume of Ascites or Pleural Effusion", 
            "safety_issue": "Yes", 
            "time_frame": "10 months"
        }, 
        "reference": {
            "PMID": "23250412", 
            "citation": "Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, Lv M, Li D, Katirai F, Shen GX, Zhang G, Feng ZH, Ye D, Huang B. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012;3:1282. doi: 10.1038/ncomms2282."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854866"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Huazhong University of Science and Technology", 
            "investigator_full_name": "Bo Huang", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Huazhong University of Science and Technology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Huazhong University of Science and Technology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}